CAMP4 THERAPEUTICS CORPORATION - Asset Resilience Ratio
CAMP4 THERAPEUTICS CORPORATION (CAMP) has an Asset Resilience Ratio of 0.34% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2018)
This chart shows how CAMP4 THERAPEUTICS CORPORATION's Asset Resilience Ratio has changed over time. See financial agility of CAMP4 THERAPEUTICS CORPORATION to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down CAMP4 THERAPEUTICS CORPORATION's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CAMP market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.93 Million | 0.34% |
| Total Liquid Assets | $1.93 Million | 0.34% |
Asset Resilience Insights
- Limited Liquidity: CAMP4 THERAPEUTICS CORPORATION maintains only 0.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CAMP4 THERAPEUTICS CORPORATION Industry Peers by Asset Resilience Ratio
Compare CAMP4 THERAPEUTICS CORPORATION's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Galapagos NV
F:GXEA |
Biotechnology | 86.45% |
|
Nanobiotix S.A
PA:NANO |
Biotechnology | 53.40% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for CAMP4 THERAPEUTICS CORPORATION (2013–2018)
The table below shows the annual Asset Resilience Ratio data for CAMP4 THERAPEUTICS CORPORATION.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 2.90% | $17.51 Million | $603.63 Million | -2.05pp |
| 2017-12-31 | 4.95% | $23.40 Million | $472.99 Million | +3.30pp |
| 2016-12-31 | 1.65% | $6.72 Million | $407.67 Million | -21.43pp |
| 2015-12-31 | 23.08% | $88.72 Million | $384.36 Million | +18.06pp |
| 2014-12-31 | 5.02% | $10.18 Million | $202.62 Million | +0.28pp |
| 2013-12-31 | 4.74% | $8.50 Million | $179.26 Million | -- |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was f… Read more